Albumin binding antibodies and binding fragments thereof
A serum albumin binding antibody or fragment thereof comprising a heavy chain variable domain having the sequence given in SEQ ID NO: 1 or SEQ ID NO:2 and/or comprising a light chain variable domain having the sequence given in SEQ ID NO:3 or SEQ ID NO:4, in particular comprising a heavy chain variable domain and a light chain variable domain having the sequence given in SEQ ID NO: 1 and SEQ ID NO:3 or a heavy chain variable domain and a light chain variable domain having the sequence given in SEQ ID NO: 2 and SEQ ID NO:4. The disclosure also extends to polynucleotides encoding the antibodies or fragments, vectors comprising same and host cells capable of expressing the polynucleotides. The disclosure further includes pharmaceutical compositions comprising the antibodies or fragments and therapeutic used of any one of the same.
1. A serum albumin binding antibody or fragment thereof comprising a heavy chain variable domain having the sequence given in SEQ ID NO: 1 or SEQ ID NO:2.
2. A serum albumin binding antibody or fragment thereof comprising a light chain variable domain having the sequence given in SEQ ID NO:3 or SEQ ID NO:4.
3. A serum albumin binding antibody or fragment thereof comprising a heavy chain variable domain having the sequence given in SEQ ID NO: 1 and a light chain variable domain having the sequence given in SEQ ID NO:3.
4. A serum albumin binding antibody or fragment thereof comprising a heavy chain variable domain having the sequence given in SEQ ID NO:2 and a light chain variable domain having the sequence given SEQ ID NO:4.
5. A serum albumin binding antibody or fragment according to any one of claims 1 to 4 , where the antibody or fragment is selected from the group consisting of a Fab, modified Fab, Fab′, F(ab′)2, Fv, scFv, bi, tri or tetra-valent antibody, Bis-scFv, diabody, triabody, tribody, DVD-Ig and BiTE.
6. A bispecific antibody fusion protein comprising:
a heavy chain comprising, in sequence from the N-terminal, a first heavy chain variable domain (VH1), a CH1 domain and a second heavy chain variable domain (VH2),
a light chain comprising, in sequence from the N-terminal, a first light chain variable domain (VL1), a CL domain and a second light chain variable domain (VL2),
wherein said heavy and light chains are aligned such that VH1 and VL1 form a first antigen binding site and VH2 and VL2 form a second antigen binding site, wherein the antigen bound by the second antigen binding site is human serum albumin and wherein the second heavy chain variable domain (VH2) has the sequence given in SEQ ID NO:1 and the second light chain variable domain (VL2) has the sequence given in SEQ ID NO: 3 or the second heavy chain variable domain (VH2) has the sequence given in SEQ ID NO:2 and the second light chain variable domain (VL2) has the sequence given in SEQ ID NO: 4, and the second heavy chain variable domain (VH2) and second light chain variable domain (VL2) are optionally linked by a disulphide bond.
7. A polynucleotide encoding an antibody or fragment as defined in any one of claim 3 , 4 , or 6 .
8. A vector comprising a polynucleotide as defined in claim 7 .
9. A host cell comprising a vector according to claim 8 .
10. A process of producing an antibody or fragment comprising expressing same from a host cell as defined in claim 9 , and isolating said antibody or fragment.
11. A pharmaceutical formulation comprising an antibody or fragment as defined in any one of claim 3 , 4 , or 6 .